Free tool
FAERS Monitor: Ontruzant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761100 or its brand name (Ontruzant, Trastuzumab-Dttb). Reports on generic versions are filed under their own applications.
Reports
32,364
Serious
30,693
95% of reports
Hospitalization
12,357
Death reported
3,644
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea3,735
- off label use3,004
- nausea2,550
- fatigue2,211
- myelosuppression1,886
- vomiting1,743
- disease progression1,698
- neutropenia1,608
- dyspnoea1,388
- pyrexia1,367
- anaemia1,311
- neuropathy peripheral1,225
- alopecia1,215
- asthenia1,179
- ejection fraction decreased1,151
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 39 |
| 2006 | 13 |
| 2007 | 80 |
| 2008 | 152 |
| 2009 | 312 |
| 2010 | 444 |
| 2011 | 393 |
| 2012 | 699 |
| 2013 | 841 |
| 2014 | 712 |
| 2015 | 856 |
| 2016 | 810 |
| 2017 | 883 |
| 2018 | 1,716 |
| 2019 | 2,305 |
| 2020 | 2,678 |
| 2021 | 3,141 |
| 2022 | 3,181 |
| 2023 | 3,217 |
| 2024 | 4,185 |
| 2025 | 3,333 |
| 2026 | 2,349 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,795 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ejection fraction decreasedSignal | 1,151 | 51.9 | 48.9 | 53,177 |
| myelosuppressionSignal | 1,886 | 35.9 | 34.3 | 60,628 |
| disease progressionSignal | 1,698 | 9.4 | 9.0 | 12,704 |
| neuropathy peripheralSignal | 1,225 | 8.5 | 8.0 | 7,990 |
| neutropeniaSignal | 1,608 | 7.8 | 7.4 | 9,421 |
| anaemiaSignal | 1,311 | 4.5 | 4.3 | 3,562 |
| alopeciaSignal | 1,215 | 4.0 | 3.8 | 2,785 |
| diarrhoeaSignal | 3,735 | 3.8 | 3.7 | 7,817 |
| pyrexiaSignal | 1,367 | 2.6 | 2.4 | 1,331 |
| vomitingSignal | 1,743 | 2.4 | 2.3 | 1,470 |
| off label useSignal | 3,004 | 2.2 | 2.2 | 2,127 |
| nauseaSignal | 2,550 | 2.1 | 2.0 | 1,515 |
| astheniaSignal | 1,179 | 2.0 | 1.9 | 634 |
| fatigue | 2,211 | 1.8 | 1.8 | 890 |
| dyspnoea | 1,388 | 1.6 | 1.5 | 315 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.